NYSE · TMO
Thermo Fisher Scientific Inc.
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
Loading market information…
NASDAQ · RGEN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Repligen Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.14% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Repligen Corporation’s next earnings report is currently expected on Feb 23, 2027, with estimated earnings per share of $0.52. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Repligen Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:16 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 29, 2025 | $0.37-7.5% vs estimate | $182.37M+4.1% vs estimate |
|---|
| Q1 2025 | Apr 29, 2025 | $0.39+11.43% vs estimate | $169.17M+3.35% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | $0.44+7.32% vs estimate | $167.55M-0.06% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
24 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $190.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$709.18+$5.03 (+0.71%)
Thermo Fisher Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.38% below the high.
$181.15-$0.33 (-0.18%)
Agilent Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.01% below the high.
€228.40+€7.00 (+3.16%)
Sartorius Stedim Biotech S.A.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
€298.50+€6.00 (+2.05%)
Sartorius AG’s quoted price sits in the upper half of its reported 52-week range, 0.27% below the high.
$72.71+$0.02 (+0.03%)
Bio-Techne Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.05% below the high.
$16.68-$0.01 (-0.06%)
Avantor, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.41% below the high.
$50.34+$0.01 (+0.02%)
Qiagen N.V.’s quoted price sits in the upper half of its reported 52-week range, 12.94% below the high.
$384.40-$0.72 (-0.19%)
Bio-Rad Laboratories, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.99% below the high.
